Beyond age: Frailty‐guided care in hematologic malignancies

Key Points

• The aim is to explore how frailty, beyond age, affects treatment decisions and outcomes in hematologic malignancies.
• Synthesis of contemporary frailty assessment tools
• Summary of evidence from multiple myeloma, acute myeloid leukemia, and aggressive lymphomas
• Discussion of frailty's impact on treatment and survival
• Frailty predicts toxicity and treatment discontinuation in hematologic malignancies
• Integrating frailty measures can enhance shared decision-making
• Targets vulnerable populations to improve quality of life and therapeutic benefit

Abstract